HER2 Key Differences and Current Approaches to Biomarker Testing
Panelist discusses how HER2 testing evaluates protein overexpression, gene amplification, and mutations. Although breast and gastric cancers typically show overexpression/amplification, other tumors more commonly harbor mutations.
Video content above is prompted by the following:
- What are the key differences between HER2 overexpression, amplification, and mutations across tumor types? How do these differences affect treatment selection?
- What is your current approach to biomarker testing for HER2 alterations across different tumor types?
Recent Videos
Related Content
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Georgios Evangelou, MD, MSc;Ioannis Vamvakaris, MD, PhD, MSc;Irene Konstantopoulou, PhD;Konstantinos Syrigos, PhD
July 10th 2024Article
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
